Imaging Studies of Kidney Cancer Using 18F-VM4-037
Stopped early · Phase 2
Conditions studied: Carcinoma, Renal Cell, Kidney Neoplasms
In brief
Background: \- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans. Researchers want to see how well it works for scans for people who have kidney cancer. Objectives: \- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney cancer. Eligibility: \- Adults at least 18 years of age with kidney cancer that will be treated with surgery. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have two positron emission tomography (PET) scans of their kidneys. They will have the scans before and after receiving an injection of 18F-VM4-037. The scans will take about 2 hours to complete. * About 3 weeks after the PET scans, participants will provide tumor tissue samples from their kidneys. * This is a scanning study only. Treatment will not be provided as part of this study.
Key facts
- Study ID
- NCT01712685
- Run by
- National Cancer Institute (NCI)
- People needed
- 12
- Starts
- 2012-10-01
- Expected to finish
- 2013-08-01
- Last updated by the study team
- 2017-01-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Subjects for whom participating would significantly delay the scheduled standard of care therapy.
- Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
- Subjects with severe claustrophobia unresponsive to oral anxiolytics.
- Other medical conditions deemed by the principle investigator (or associates) or sponsor to make the subject ineligible for protocol procedures.
- Female subject is pregnant or nursing
- The site of the target lesion must not have been part of a radiation portal within 6 months of enrollment.
- Subjects having received another investigational agent within 1 month before administration of 18F-VM4-037.
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.